For example, Infliximab, ananti-TNFα monoclonal antibody, reduced IL-8/CXCL8 and MCP-1/CCL2levels.2 CP481, a CCR1 antagonist, hasshown a 90% decrease in the chemotactic activities in synovial fluidsamples of RA patients.117 ABX-IL-8, amonoclonal antibody, neutralizes IL-8/CXCL8 and shows promise in treatingRA (phase II clinical trials).72 Anotheragent, ABN-912, targets MCP-1/CCL2 chemokine and can potentially bebeneficial in RA. This evidence concerns the gene CCL2 and rheumatoid arthritis.